Updated

A large Swedish study of nearly 15,000 people with bipolar disorder found that semaglutide, the active drug in Ozempic and Wegovy, was associated with a 21% lower risk of psychiatric hospitalization, suggesting benefits beyond weight loss and diabetes control. Researchers believe effects on inflammation and brain pathways may help stabilize mood, though other GLP-1 drugs did not show the same association.